Oncternal Therapeutics, Inc.
ONCT · NASDAQ
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.04 | -0.00 | -0.13 | 1.44 |
| FCF Yield | -102.05% | -69.79% | -3.63% | -0.72% |
| EV / EBITDA | 11.25 | -0.35 | -20.56 | -132.82 |
| Quality | ||||
| ROIC | -131.57% | -73.62% | -35.56% | -15.53% |
| Gross Margin | -3,690.19% | 87.99% | 96.08% | -255.56% |
| Cash Conversion Ratio | 0.81 | 0.83 | 0.85 | 1.02 |
| Growth | ||||
| Revenue 3-Year CAGR | -43.34% | -23.86% | 21.18% | 10.21% |
| Free Cash Flow Growth | 12.37% | -38.04% | -51.98% | -4.47% |
| Safety | ||||
| Net Debt / EBITDA | -2.85 | 0.82 | 2.91 | 6.71 |
| Interest Coverage | 0.00 | 0.00 | 0.00 | 0.00 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 1.74 | 0.00 | 0.00 |
| Cash Conversion Cycle | 279.78 | -5,694.44 | -4,151.12 | -34.77 |